| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MTAP |
| Uniprot No | P78559 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MTAP重组蛋白的参考文献示例(注：部分信息为示例性概括，建议通过学术数据库检索获取具体文献)：
---
1. **文献名称**：**"Cloning and expression of human methylthioadenosine phosphorylase (MTAP) and its role in purine metabolism"**
**作者**：Hori, H., et al.
**摘要**：该研究报道了人源MTAP基因的克隆及其在大肠杆菌中的重组表达，分析了重组蛋白的酶动力学特性，并探讨了MTAP在嘌呤补救合成途径中的作用及其与肿瘤代谢的关系。
---
2. **文献名称**：**"Structural insights into MTAP deficiency and its therapeutic implications in cancer"**
**作者**：Kryukov, G.V., et al.
**摘要**：通过X射线晶体学解析了重组MTAP蛋白的三维结构，揭示了其底物结合位点及突变导致功能缺失的机制，为靶向MTAP缺失型肿瘤的药物设计提供了结构基础。
---
3. **文献名称**：**"Recombinant MTAP as a biomarker for CDKN2A-deficient cancers"**
**作者**：Smith, J., & Jones, R.
**摘要**：研究利用重组MTAP蛋白开发了免疫检测方法，验证了MTAP蛋白缺失与CDKN2A基因缺失在多种癌症中的关联性，提出其作为诊断标志物的潜力。
---
4. **文献名称**：**"Enzymatic characterization of recombinant MTAP and its application in methionine salvage pathway engineering"**
**作者**：Kraus, J.P., & Bower, S.
**摘要**：分析了重组MTAP蛋白在甲硫氨酸回收途径中的催化效率，并通过代谢工程改造酵母菌株，证明MTAP的过表达可提升甲硫氨酸再生能力，为工业生物技术提供新策略。
---
**注意**：以上文献信息为示例性概括，实际文献需通过PubMed、Web of Science等数据库检索。若需具体文献，建议使用关键词“MTAP recombinant protein”或“methylthioadenosine phosphorylase expression”进行查询。
**Background of MTAP Recombinant Protein**
Methylthioadenosine phosphorylase (MTAP) is a critical enzyme involved in purine salvage and methionine recycling pathways. It catalyzes the conversion of methylthioadenosine (MTA), a byproduct of polyamine synthesis, into adenine and 5-methylthioribose-1-phosphate. These products are further utilized in adenosine triphosphate (ATP) regeneration and methionine biosynthesis, linking MTAP to cellular metabolism and homeostasis.
The MTAP gene is located on chromosome 9p21. a region frequently deleted in cancers, including gliomas, pancreatic cancer, and leukemias. Loss of MTAP is often co-deleted with the tumor suppressor gene *CDKN2A*, contributing to dysregulated cell cycle progression and metabolic vulnerabilities. This deletion has spurred interest in MTAP as a biomarker and therapeutic target.
Recombinant MTAP protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), enables detailed study of its enzymatic mechanisms, structural properties, and interactions. Purification techniques, such as affinity chromatography, yield high-purity MTAP for functional assays, inhibitor screening, and structural biology (e.g., X-ray crystallography). Researchers also leverage MTAP-deficient cell lines to explore metabolic dependencies, such as heightened sensitivity to purine analogs, which may inform precision therapies.
In drug discovery, MTAP recombinant protein aids in developing small-molecule inhibitors or substrate analogs to exploit metabolic vulnerabilities in MTAP-deficient cancers. Additionally, it serves as a tool for diagnostic assay development, given its association with specific malignancies.
Overall, MTAP recombinant protein is pivotal in elucidating metabolic adaptations in cancer, advancing targeted therapies, and understanding the interplay between epigenetics and metabolism in disease. Its study bridges basic biochemistry and translational oncology, offering insights into personalized treatment strategies.
(Word count: 247)
×
